The International Herald Tribune also says "Broader financial turmoil threatens biotech's innovation":
So far this year, public and private biotechnology companies have raised $5.6 billion . . . . That is only one-third the amount in all of 2007 and likely to be the lowest amount since 2002.
As noted yesterday, it is cold comfort to a patient to contemplate on how cheap a drug would be if only it existed when the non-existence is due to ideologues' insistence that the price be set too low to justify investment in development.
One definition of an ideologue is someone who thinks it fine that others suffer to maintain the purity of his abstractions about how things ought to be.